Notice of Change in Expiration Date and Application and Submission Information for PAR-16-138 "Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25)"

Notice Number: NOT-CA-18-081

Key Dates
Release Date:   June 26, 2018

Related Announcements
PAR-16-138
NOT-CA-18-082

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this notice is to inform interested applicants that the expiration date and Application and Submission Information for the Funding Opportunity Announcement (FOAPAR-16-138", Cancer Research Education Grants Program to Promote Diversity Research Experiences (R25)" have been changed. 

The FOA has been modified as follows:

Part 1. Overview Information

Key Dates

Currently reads:

Expiration Date

September 8, 2018

Modified to read:

Expiration Date

January 8, 2019

Part 2. Full Text of Announcement

Section IV. Application and Submission Information

Currently reads

Planned Enrollment Report

When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide. 

PHS 398 Cumulative Inclusion Enrollment Report

When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide. 

Modified to read

PHS Human Subjects and Clinical Trials Information

Form only available in FORMS-E application packages for use with due dates on or after January 25, 2018.

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study: All instructions in the SF424 (R&R) Application Guide must be followed.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Behrous Davani, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6098
Email: behrous.davani@nih.gov